Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evalulation Digitek Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation\ Avandia Case Evaluation Tequin Case Evaluation Ketek Case Evaluation
Permax Case Evaluation Zelnorm Case Evaluation Vytorin Case Evaluation Dostinex Case Evaluation Bextra Case Evaluation Natrecor Case Evaluation

Federal Preemption Alert: Drug Injury Claims May Be Prohibited

Free Case Evaluation

Adderall Information

What is Adderall?

Adderall® is the name under which Shire markets a prescription medication for ADHD generically called D-Amphetamine Salt Combo. Sales of Adderall were suspended in Canada in February 2005 following reports of sudden deaths and cardiovascular problems in patients taking Adderall. At the time Health Canada suspended sales of Adderall, the US FDA issued a statement saying it was evaluating the data.

FDA Advisory Panel Recommends Black Box Warning for Adderall and Other ADHD/ADD Drugs
Sudden deaths, heart attacks, and strokes in both children and adults taking drugs to treat attention deficit hyperactivity disorder (ADHD) have been reported to the FDA. These adverse event reports led the agency to, in February 2006, convene an advisory panel committee of outside drug-safety experts.


Adderall Sales Suspended by Health Canada
In February 2005, Health Canada suspended sales of the once-daily formulation of the attention-deficit disorder drug Adderall, citing a risk that it may cause sudden deaths. Adderall is one of the most popular drugs for people with the widely-diagnosed condition more formally known as attention deficit hyperactivity disorder (ADHD).


Public Health Advisory for Adderall and Adderall XR
Health Canada, the Canadian drug regulatory agency, has suspended the sale of Adderall XR in the Canadian market. Adderall XR is a controlled release amphetamine used to treat patients with Attention Deficit Hyperactivity Disorder (ADHD). The Canadian action was based on U.S. post-marketing reports of sudden deaths in pediatric patients.


FDA Statement on Adderall - February 2005
FDA is aware of Health Canada's decision to suspend sales, but not revoke the approval in Canada, of the drug Adderall as a treatment for Attention Deficit and Hyperactivity Disorder (ADHD). FDA has been in close consultation with the Canadian authorities regarding the basis for their action.


Canadian Advisory on Adderall
Health Canada is informing Canadians that it has instructed Shire BioChem Inc., the manufacturer of ADDERALL XR® to withdraw the drug from the Canadian market. Health Canada has suspended the market authorization of the product due to safety information concerning the association of sudden deaths, heart-related deaths, and strokes in children and adults taking usual recommended doses of ADDERALL® and ADDERALL XR®.


Adderall and Adderall XR Information at US FDA
FDA ALERT [08/2005] Health Canada Announces Return of Adderall to the Canadian Market.
FDA ALERT [02/2005] Health Canada Suspends Marketing of Adderall


Adderall Class Actions
Our law firm believes that people injured by Adderall are better served by having an individual lawsuit filed instead of joining a class action lawsuit.


Adderall and Legal Compensation
How to get legal compensation for an Adderall injury or death.



Drug Injury Watch: Adderall News and Commentary


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer